Report Overview

The Australian Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics Market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder in which there is inflammation of nerve roots and peripheral nerves and destruction of the fatty protective covering(myelin sheath) of the nerve fibres. Myelin allows nerve fibres to transmit signals very rapidly (40-60 meters/second). Loss or damage to myelin can cause slowing or blockage of the nerve signals and can lead to loss of nerve fibres. This causes weakness, paralysis and/or impairment in motor function, especially of the arms and legs. Sensory disturbance may also be present.

CIDP is a rare disorder that can affect any age group and CIDP affects males twice as often as females and the average age of onset is 50. Some affected individuals may follow a slow steady pattern of symptoms while others may have symptoms that stabilize and then relapse.



Market Drivers and Restraints

The prevalence of CIDP has increased dramatically, paving the way for the growth of the Australian market for Chronic Inflammatory Demyelinating Polyneuritis (CIDP). The increasing incidence of CIDP is a major concern in the medical sector. Therefore, high unmet need for advanced treatment options for the disease is likely to bring new opportunities for market players over the forecast period.

Several public and private organizations launched initiatives for R&D activities that produced positive results in the market of CIDP. Remarkable results have been achieved through rigorous research and development efforts and clinical trials. Several new drugs are introduced following recent TGA approvals, which also spur growth of the CIDP market. Other factors supporting the market growth comprise surging awareness of the disease and government endeavours on the same.

The high cost of intravenous immunoglobulin treatment, as well as the adverse effects associated with it, such as hypotension, nausea, lower back discomfort, flushing, chills, wheezing, and so on, continue to limit the market's expansion.